New Targeted Drug for Stomach Cancer: Ramucirumab

One of the most prestigious oncology journals, The Lancet Oncology, published findings showing that targeted drug Ramucirumabprolonged survival in advanced stomach cancer unresponsive to standard treatment.

Stomach cancer is among the four most common cancers worldwide. Approximately twenty thousand people develop it annually in Türkiye. Men are at greater risk, and older people more often affected. Diet matters: excess salt, fried, barbecued or smoked foods and little produce contribute. Additive-containing foods, alcohol, tobacco and Helicobacter pylori, which causes ulcers and gastritis, are other factors.

Socioeconomic and cultural conditions, geography and genetics sustain its importance. Refrigeration and less salted or smoked food have reduced worldwide rates. Türkiye's recent rise, unlike global trends, reflects more smoking and alcohol, ready-made food, reused frying oils and uncontrolled chemicals in produce and other foods.

Few early symptoms make diagnosis and treatment difficult. Early standard treatment extensively removes the stomach and surrounding nodes, with protective adjuvant chemotherapy or radiotherapy according to risk. Detection before spread outside the stomach provides high cure rates.

However, many arrive beyond operability, with spread to liver, abdominal organs, lungs or bones, currently without cure. Chemotherapy and smart drugs aim to prolong life and improve quality. Herceptin, used in breast cancer, entered stomach treatment after Her2 receptors were identified. It benefits nearly 1/5 of patients and significantly prolongs life compared with conventional chemotherapy. Yet available advanced-disease options remain insufficient and unsatisfactory for patients and oncologists.

New research now offers hope and suggests its positive results will soon change routine practice.

The prestigious Lancet Oncology published findings that targeted ramucirumab prolonged survival in advanced stomach cancer unresponsive to standard therapy.

Ramucirumabis a targeted monoclonal antibody. It blocks VEGFR-2 and prevents development of tumor-feeding vessels. In previously treated, unresponsive patients aged 24-87, numbering 355 with advanced stomach cancer, it prolonged survival.

Demonstrating benefit from blocking VEGFR-2 signaling, the research is a positive treatment development.

Dear readers, cancer treatment requires knowledge, technology and above all love. Every advance guides oncologists and gives patients hope. May all beautiful tomorrows be yours with loved ones.